Chronic Lymphocytic Leukemia | Specialty

Dr. O'Brien Discusses Combination Venetoclax in CLL

August 22nd 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.

Dr. Brander Discusses the Frontline Treatment of CLL

August 14th 2018

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

O'Brien Shares Overview of CLL Sequencing

August 10th 2018

Susan M. O'Brien, MD, discusses some of the latest intriguing data in the treatment of chronic lymphocytic leukemia and what this means for physicians and patients.

Dr. Barrientos on Advances in the Treatment Landscape for Patients With CLL

August 8th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses advances in the treatment landscape for patients with chronic lymphocytic leukemia (CLL).

Dr. O'Brien on Sequencing Small Molecule Inhibitors in CLL

August 6th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses sequencing small molecule inhibitors in chronic lymphocytic leukemia (CLL).

Rai Helped Launch an Age of Innovation in Leukemia

August 5th 2018

Kanti R. Rai, MD, has been a leader in the diagnosis and treatment of chronic lymphocytic leukemia for more than 40 years. He was honored in the Hematologic Malignancies category with a 2017 Giants of Cancer Care® award.

Talley Traces Developments in Chronic Leukemias

August 3rd 2018

Robert L. Talley, MD, elaborates on the clinical trial findings that are shifting standards of care in chronic leukemias.

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

July 26th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Expert Reviews Current State of CLL Treatment

July 24th 2018

Danielle Brander, MD, highlights how recent advances are changing the field of chronic lymphocytic leukemia and what it means for patients and their oncologists.

Umbralisib Shows Promise in Relapsed/Refractory CLL

July 23rd 2018

Anthony R. Mato, MD, MSCE, discusses the next steps for umbralisib and the biggest challenges still facing patients with chronic lymphocytic leukemia.

Dr. Brander on the Treatment Landscape for Patients With High-Risk CLL

July 20th 2018

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

Expert Shares Insights on CLL Treatment Paradigm

July 20th 2018

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

Regimen Shows Potential for Reducing TLS Risk in CLL

July 17th 2018

Kerry Rogers, MD, discusses the feasibility of a new treatment for tumor lysis syndrome and what research still needs to be done with these agents in chronic lymphocytic leukemia.

Despite New Treatments in CLL, Comparative Data and Guidance Slow to Emerge

July 15th 2018

With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.

Dr. Barrientos on the Challenges in CLL

July 14th 2018

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.

Dr. Talley on Clinical Trials for Patients With Chronic Leukemias

July 13th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.

Dr. Talley on the CAPTIVATE Trial in CLL

July 10th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses the CAPTIVATE trial in patients with chronic lymphocytic leukemia (CLL).

CLL: The Rapidly Evolving Treatment Landscape

June 28th 2018

CAPTIVATE and iNNOVATE Clinical Trial Results for CLL

June 28th 2018

Addressing the Unmet Needs for the Treatment of CLL

June 28th 2018